Travere Therapeutics, Inc. today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will host a ...

Thursday's IBD 50 Growth Stocks To Watch pick, biotech leader Travere Therapeutics TVTX, is approaching its latest buy point ...

Chugai Pharma to acquire Tokyo-based clinical biopharmaceutical company, Renalys Pharma: Tokyo, Japan Saturday, October 25, 2025, 09:00 Hrs [IST] Renalys Pharma, Inc., a privately ...

Renalys Pharma, Inc. (Headquarters: Tokyo; Representative Director Chaiman & CEO; BT Slingsby; "Renalys") and Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo; President & CEO: Osamu Okuda; ...

As the industry's competition in the rare kidney disease IgA nephropathy (IgAN) heats up in the U.S., Roche’s Chugai Phar | Last year, Japan's Renalys picked up certain Asian rights to the IgAN ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney Week ...

SAN DIEGO, October 10, 2025--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of ...

First Trust Small Cap Growth AlphaDEX® Fund ETF has a unique sector mix and strong performance vs. peers. See more on FXC ETF ...

Roche's Japanese unit Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia. Chugai is paying JP 15 billion ($98 million) ...